Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...

COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that Combivent Respimat (ipratropium bromide and albuterol) inhalation ...

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday. BI Pharmaceuticals announced the launch of ...

Combivent Respimat Transition Almost Complete Transition of Combivent Respimat is nearly complete as Boehringer Ingelheim plans to cease distribution of Combivent MDI in May. Boehringer Ingelheim ...

COMBIVENT MDI and COMBIVENT RESPIMAT are the only short-acting bronchodilator products that offer two different medicines in a single inhaler. Clinical studies in patients with COPD have shown that ...